Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Xanodyne Receives Approval From The U.S. Food And Drug Administration For ZIPSOR(TM) (diclofenac Potassium) Liquid Filled Capsules
Xanodyne Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zipsor (diclofenac potassium) Liquid Filled Capsules, a new treatment option indicated for relief of mild to moderate acute pain in adults (18 years of age or older).
generic viagra online
Preseason Shoulder Strength May Determine Injury Severity For Baseball Pitchers
Athletic injuries can derail any player"s ability to compete, but for a baseball pitcher his shoulder strength and control is critical. A new study to be presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, suggests that testing a pitcher"s shoulder strength through a series of exercises during the preseason may help create a focused strength training program to prevent serious injury during the season.
News of the day
Even At High Doses, Gadolinium-Based Contrast Agents Cannot By Themselves Cause Patients To Develop Nephrogenic Systemic Fibrosis
Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the Mayo Clinic Florida, Jacksonville, FL. NSF is a rare and serious syndrome that leads to fibrosis of the skin, joints and even internal organs. Some research indicates NSF is caused by gadolinium-based contrast agents that are commonly used today during MR procedures.
Oncology

Conference: Discovery Partnerships: Academia & Industrial Interactions

Opal Events is proud to present our next exciting conference Drug Discovery Partnerships: Academia & Industrial Interactions , to be held at the Hyatt Regency in Boston on October 28-30, 2009. Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs. With key products suffering patent expiration in coming years, the need for new approaches to accelerate development of new chemical entities to treat severely unmet medical needs is more urgent than ever. This event brings together pharmaceutical companies, universities, small biotechnology enterprises, government agencies, for-profit and not-for profit research institutions to exchange ideas, make connections and discuss opportunities to create an environment that will foster pharmaceutical innovation. Overcome Your Most Critical Challenges in forming Academia-Industrial Partnerships: - Understand Specific Requirements Regarding Investigational New Drug (IND) Application and Approval Process - Maximize the Value and Minimize the Risk by Partnering with the Right Entity - Hear Insider"s Guide to Securing Grant Money for Your Drug Discovery Project - Examine Recent United States Decisions and their Impact on Pharmaceutical and Academia Patenting - Improve Speed to Market with Seamless Alignment on Science and Technology Who Will Attend? Pharmaceuticals, Biotechs, Academia, Foundations, Technology Companies and CRO"s - Managers/ Directors/ VP"s/ Faculty Advisors of: - External Research Collaboration - Scientific Affairs - Business Development - Partnership/ Alliance Management - Office of Technology Transfer - Academic Screening Facilities - School of Medicine/ Life Sciences/ Pharmacy - Grants Manager - Program Officer - Research & Development Sponsorship and Exhibiting Opportunities If you are interested in sponsorship, exhibiting or speaking opportunities, please contact Kay Ye at kye@opalevents.org or 212 532-9898, extension 263. Register Registration is already open on our website here. Sign up today! Opal Events


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009